To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in
normal clinical practice, in larger patient numbers. Patients will be assessed at baseline,
at each follow-up visit (follow-up visits are variable as per physician discretion) and at
final follow-up visit.
- A diagnosis of Primary Open-Angle Glaucoma or Ocular Hypertension newly diagnosed OR
presenting with insufficiently controlled IOP on current medication (in the opinion
of the treating physician)
- Patient is having both eyes treated
- Contraindications per product labelling will apply.
- Patients with any ophthalmic co-morbidity with an influence on visual field
deterioration or optic nerve head damage.